血清β-同核素升高预测认知能力下降和发展为痴呆症
Nayeong Kong1, Joon Hyung Jung2,
1Department of Psychiatry, Keimyung University School of Medicine, Daegu, Korea (the Republic of).
Journal of neurology, neurosurgery, and psychiatry
|September 23, 2025
概括
血清β-同核素是一种潜在的阿尔茨海默病 (AD) 生物标志物,与认知能力下降和痴呆症进展有关. 较高的水平表明痴呆风险增加,即使考虑到AD病理.
科学领域:
- 神经科学是一个神经科学.
- 生物标志物发现发现
- 阿尔茨海默氏症疾病研究研究
背景情况:
- 突触功能障碍是阿尔茨海默病 (AD) 发病的核心原因.
- 贝塔 (β) - 同核蛋白是一种大脑蛋白,是突触功能障碍的潜在生物标志物.
- 它在AD的纵向临床进展中的作用需要进一步研究.
研究的目的:
- 调查血清β-同核素水平与AD病理学的关联.
- 为了检查血清β-synuclein与认知表现之间的关系.
- 评估血清β-synuclein与痴呆症进展风险之间的联系.
主要方法:
- 对来自AD神经成像倡议队列的474名参与者的血清β-synuclein水平的分析.
- 血清β-synuclein与脑脊液 (CSF) AD病理 (tau,amyloid-β) 的相关性.
- 统计建模 (线性回归,混合效应,Cox模型) 来评估认知和痴呆风险.
主要成果:
- 血清β-synuclein的升高与CSF酸化tau和总tau的增加相关,并且降低了CSF粉样β (1-42).
- 较高的血清β-同核素预测了较差的基线认知和在多个尺度上加速认知衰退.
- 血清β-synuclein水平的增加与84个月内痴呆症进展的风险更高有关.
结论:
- 血清β-同核蛋白显示为阿尔茨海默病进展和认知衰退的生物标志物具有前途.
- 研究结果表明,血清β-同核素可能是痴呆风险的独立预测因子.
- 需要进一步的研究来验证其在阿尔茨海默氏病原和临床实用性中的作用.
相关概念视频
Neural Regulation
43.1K
Digestion begins with a cephalic phase that prepares the digestive system to receive food. When our brain processes visual or olfactory information about food, it triggers impulses in the cranial nerves innervating the salivary glands and stomach to prepare for food.
43.1K
Alzheimer's Disease: Overview
1.6K
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
1.6K
Dementia
526
Dementia is a collective term for cognitive disorders primarily affecting memory, thinking, and reasoning. It is not a specific disease but a syndrome, with Alzheimer's disease being the most common cause, accounting for approximately 60-80% of cases. Other types include vascular dementia, Lewy body dementia, and frontotemporal dementia. Dementia affects millions worldwide, particularly older adults, though it is not a normal part of aging.
The progression of dementia is generally gradual....
The progression of dementia is generally gradual....
526
Alzheimer's Disease: Treatment
825
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
825


